Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Introduce Vaccination Facilitation System for Wholesalers, Medical Institutions
November 2, 2020
- OxyContin Gets Delayed Approval in Japan with Special Distribution Scheme Now in Place
October 30, 2020
- MHLW’s Switch OTC Panel to Take on Mere Advisory Role in Line with Govt’s Policy
October 30, 2020
- Forxiga’s Heart Failure Use Now in Line for November Approval, Covers HFrEF Patients
October 30, 2020
- Japan to Receive 50 Million Doses of Moderna COVID-19 Vaccines via Takeda
October 29, 2020
- Chuikyo Reps Agree on Need to Validate Current Cost-Effectiveness Analysis Scheme
October 29, 2020
- Pharmaceutical Development Council Holds 1st Meeting; Aiming to Sort Out Priority Issues by March
October 29, 2020
- Bill to Amend Immunization Act Submitted to Diet
October 28, 2020
- MHLW Issues Notification on Establishing COVID-19 Vaccination Systems
October 28, 2020
- PM Suga Vows to Work towards Annual Price Revisions: Diet Policy Speech
October 27, 2020
- Reform Minister Asks MHLW to Facilitate Global Launch of Japan-Originated Medical Software Programs
October 27, 2020
- 1st Working Group Meeting for Prioritization of “Stable Supply Medicines” Set for Early November
October 26, 2020
- MHLW Continues to Collect Info on WHO-Led Study on Veklury
October 26, 2020
- MHLW Wants Distribution Improvement Confab by Year-End, Reckless Discounts Seen with Pricey Meds
October 22, 2020
- Xenograft Library Derived from Japanese Cancer Patients Now Up and Running
October 22, 2020
- No Skipping of Japanese Translation for COVID-19 Vaccine Dossiers: PMDA Official
October 21, 2020
- PMDA Sees Studies on Preventive Effect as a “Must” for Coronavirus Vaccines: Official
October 21, 2020
- Keidanren Calls for Clearer Classification Criteria for “Software as a Medical Device” to Promote Development
October 21, 2020
- Vice Health Minister Vows to Work on Law Amendment to Set Up Sound Vaccination Scheme
October 20, 2020
- Japan Cannot Boast of Its Development Status of COVID-19 Vaccines/Drugs: LDP Health Committee Chair
October 20, 2020
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…